Cureus,
Journal Year:
2023,
Volume and Issue:
unknown
Published: Aug. 4, 2023
A
39-year-old
Japanese
male
patient
presented
with
a
chief
complaint
of
gross
hematuria
persistent
for
two
months.
However,
no
relevant
findings
in
the
patient’s
medical
and
family
history
were
observed.
He
was
diagnosed
muscle-invasive
bladder
cancer,
clinical
stage
T2bN0M0.
After
four
courses
neoadjuvant
chemotherapy
gemcitabine
cisplatin,
tumor
size
reduced
by
approximately
30%.
The
underwent
robot-assisted
radical
cystectomy
standard
lymph
node
dissection
followed
intracorporeal
ileal
conduit
reconstruction.
Histologically,
as
high-grade
urothelial
carcinoma
invading
fatty
tissue
surrounding
metastasizing
to
nodes,
pathological
ypT3aypN2M0.
Four
months
after
surgery,
multiple
metastases
detected,
treatment
pembrolizumab
initiated
immediately.
did
not
respond
pembrolizumab.
Therefore,
third-line
enfortumab
vedotin
(EV)
initiated.
Thereafter,
metastatic
lesion
shrank
quickly,
lesions
almost
disappeared
EV
administration.
Although
new
observed
at
other
sites,
there
has
been
regrowth
date.
EV-related
adverse
events
during
follow-up.
Eighteen
remains
alive
metastases.
sequence
should
be
considered
maximize
therapeutic
effect
EV,
and,
consequently,
administering
early
possible
may
important.
Cureus,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 25, 2025
Recently,
enfortumab
vedotin
has
emerged
as
a
promising
treatment
option
for
metastatic
urothelial
carcinoma.
Although
it
does
not
require
dosage
adjustments
in
patients
with
renal
failure,
its
safety
and
efficacy,
particularly
those
undergoing
dialysis,
remain
unclear.
We
report
case
of
carcinoma
patient
hemodialysis
who
achieved
complete
response
to
therapy
without
severe
adverse
events.
This
was
maintained
two
years
any
complications.
Our
demonstrates
that
can
be
safely
administered
long-term
hemodialysis.
Pharmaceuticals,
Journal Year:
2025,
Volume and Issue:
18(2), P. 180 - 180
Published: Jan. 29, 2025
The
emergence
of
antibody–drug
conjugates
(ADCs)
has
transformed
the
treatment
landscape
a
variety
cancers.
ADCs
typically
consist
three
main
components:
monoclonal
antibody,
chemical
linker,
and
cytotoxic
payload.
These
integrated
therapeutic
modalities
harness
benefits
each
component
to
provide
response
that
cannot
be
achieved
by
conventional
chemotherapy.
Antibodies
play
roles
in
determining
tumor
specificity
through
target-mediated
uptake,
prolonging
circulation
half-life
payloads,
providing
additional
mechanisms
action
inherent
original
thus
significantly
contributing
overall
performance
ADCs.
However,
have
unique
safety
concerns,
such
as
drug-induced
adverse
events
related
uptake
ADC
normal
tissues
(so-called
“on-target,
off-tumor
toxicity”)
platform
toxicity,
which
are
partially
derived
from
limited
antibodies.
Identifying
suitable
target
antigens
impacts
clinical
success
requires
careful
consideration,
given
multifaceted
aspects
this
modality.
This
review
briefly
summarizes
representative
antibodies
efficacy
Key
considerations
for
selecting
cell
surface
therapy
also
highlighted.
Japanese Journal of Clinical Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 31, 2025
Abstract
Objective
This
study
aimed
to
assess
the
influence
of
modifying
dose
enfortumab
vedotin
(EV)
monotherapy
in
patients
with
advanced
urothelial
carcinoma
(UC).
Methods
We
retrospectively
evaluated
consecutive
metastatic
UC
who
had
received
EV
following
platinum-based
chemotherapy
and
immune
checkpoint
inhibitor
therapy
at
our
institution
between
December
2021
June
2024.
The
relative
intensity
(RDI),
reason
for
adjustments,
overall
survival
(OS)
were
analyzed.
Results
Overall,
49
enrolled,
which
16
(32.7%),
21
(42.9%),
12
(24.4%)
RDI
>80%,
60%–80%,
<60%,
respectively.
was
discontinued
3
(6.1%),
interrupted
22
(44.9%),
reduced
26
(53.1%)
patients.
In
particular,
because
adverse
events
(AEs)
77%
patients,
patient
preference
or
attending
physician’s
discretion
23%.
reduction
occurred
AEs
23%
discretion.
median
duration
exposure
<60%
3.8,
4.8,
7.8
months,
These
three
groups
showed
no
significant
difference
OS
from
introduction
(median,
8.8
months
vs.
12.9
15.1
months;
P
=
.104).
response
9.9
<
60%.
Conclusion
cases
effective
management,
decreasing
during
does
not
negatively
impact
outcomes.
Therapeutic Advances in Urology,
Journal Year:
2024,
Volume and Issue:
16
Published: Jan. 1, 2024
Antibody-drug
conjugates
and
bicycle
toxin
represent
a
tremendous
advance
in
drug
delivery
technology
have
shown
great
promise
the
treatment
of
urothelial
cancer.
Previously
approved
systemic
therapies,
including
chemotherapy
immunotherapy,
are
often
impractical
due
to
comorbidities,
outcomes
for
patients
with
advanced
disease
remain
poor,
even
when
receiving
therapy.
In
this
setting,
antibody-drug
emerged
as
novel
treatments,
dramatically
altering
therapeutic
landscape.
These
drugs
harness
unique
designs
consisting
antibody
or
peptide,
linker,
cytotoxic
payload
more
targeted
than
conventional
chemotherapy,
thus
eliminating
malignant
cells
while
reducing
toxicities.
Potential
targets
investigated
cancer
include
Nectin-4,
TROP2,
HER2,
EphA2.
Initial
clinical
trials
demonstrated
efficacy
refractory
cancer,
well
improvement
quality
life.
initial
studies
led
FDA
approval
two
conjugates,
enfortumab
vedotin
sacituzumab
govitecan.
Moreover,
being
studied
ongoing
frontline
localized
highlight
potential
additional
future
therapies
targets,
antibodies,
immunomodulatory
payloads,
structural
enhancing
safety.
There
is
increasing
evidence
that
combinations
other
especially
improve
outcomes.
The
combination
pembrolizumab
was
recently
first-line
carcinoma.
Despite
these
drugs,
robust
predictive
biomarkers
needed
determine
who
would
maximally
benefit.
This
review
surveys
rationale
current
state
new
describes
directions
actively
explored.
Journal of Chemotherapy,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 13
Published: April 17, 2024
A
time-course
questionnaire
survey
using
the
chemotherapy-induced
taste
alteration
scale
(CiTAS)
was
conducted
in
patients
with
advanced
urothelial
carcinoma
(UC)
treated
systemic
chemotherapy
and/or
immunotherapy.
total
of
37
receiving
therapy
enfortumab
vedotin
(EV),
platinum-based
and
immune
checkpoint
inhibitors
were
included
this
study.
No
significant
changes
observed
any
CiTAS
subscales
during
inhibitor
treatment,
while
EV
induced
dysgeusia.
Among
10
EV,
dysgeusia
associated
a
substantial
negative
effect
on
health-related
quality-of-life
domains,
particularly
global
health
status/QOL
(mean
±
standard
deviation:
52
19
group
vs
89
13
non-dysgeusia
group)
mental
component
summary
(47
5.1
53
2.0).
The
fatigue
symptom
score
higher
at
post-third
cycle
16
15
17).
Severe
can
be
by
therapy,
which
is
usually
not
other
therapies
for
UC.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(9), P. 1725 - 1725
Published: April 28, 2024
Background:
In
the
EV-301
trial,
enfortumab
vedotin
prolonged
survival
in
patients
with
locally
advanced
or
metastatic
urothelial
carcinoma
previously
treated
platinum-based
therapy
and
programmed
cell
death
1/programmed
death-ligand
1
inhibitor.
However,
real-world
Asian
data
are
limited,
potential
prognostic
markers
non-existent.
We
aimed
to
investigate
for
patients.
Methods:
retrospectively
enrolled
61
Japanese
at
our
hospital
affiliated
hospitals
between
January
2019
September
2023.
Results:
Enrolled
(38
men,
23
women;
median
age
74
[IQR:
68–79]
years)
had
bladder
cancer
(26
patients)
upper-tract
(35
patients).
Fifty-four
reported
adverse
events
(grade
>3
12).
Skin
disorders,
pruritus,
neuropathy
were
common
effects.
The
overall
was
17.1
months
(95%
confidence
interval:
10.0–not
applicable).
multivariate
analysis,
C-reactive
protein
level
an
independent
marker
predicting
favorable
vedotin.
Patient
characteristics
did
not
differ
protein-high
-low
groups.
Conclusions:
Our
study
provides
showing
that
similar
trial.
Additionally,
might
be
considered
a
of
such
